Source: Annual Congress 2011 - Mucus in airway diseases: bad or good partner?
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Burgel (Paris , France). Targeting mucus as a new therapeutic avenue?. Annual Congress 2011 - Mucus in airway diseases: bad or good partner?

Member's Comments

No comment yet.

Related content which might interest you: Targeting the arginase pathway: potential developments as new avenues for treatment Source: Annual Congress 2004 - Arginase: a novel target and marker for asthma? Year: 2004 Novel therapeutics for CF Source: International Congress 2019 – Future of cystic fibrosis care: insights from the Lancet Commission Year: 2019 Clinical implications and opportunities for new drug therapies Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications Year: 2008 Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19 Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020 Year: 2020 Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies? Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021 Year: 2022 Novel targets and emerging therapies in MPM Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021 Filling in the gaps- Translational research to develop new therapies  Source: International Congress 2017 – Bronchiectasis: from guidelines to real life Year: 2017 COPD – will new insights into molecular pathology define new therapies? Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 Fibrocytes: potential new therapeutic targets for pulmonary hypertension? Source: Eur Respir J 2010; 36: 1232-1235 Year: 2010 Modifying remodelling and repair in ILD: a new therapeutic approach? Source: Annual Congress 2006 - PG15 - Remodelling and repair in lung disease Year: 2006 Revisiting α1-antitrypsin therapy in cystic fibrosis: can it still offer promise? Source: Eur Respir J 2007; 29: 229-230 Year: 2007 Reversing glucocorticoid resistance as a new therapeutic strategy Source: Annual Congress 2012 - The promise of new drugs for treating asthma and COPD Year: 2012 Lots of promising targets and biomarkers, but how can we deliver the next generation of severe asthma trials? Source: International Congress 2019 – Beyond T2 mechanisms in asthma: who are the other players? Year: 2019 Proteases as tools for diagnosis and novel therapeutics Source: ERS Research Seminar 2015 Year: 2015